Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

To be considered for this study, you must have already completed a specific previous study about sotatercept for Cpc-PH (called the MK-7962-007 study, also known as CADENCE). You need to have finished that study without stopping the treatment early and be well enough to safely join this new, extended study.

There are certain health conditions or situations that would prevent someone from joining. For example, if you have other types of high blood pressure in the lungs (called WHO Group 1, 3, 4, or 5 PH) that are not the focus of this study. You also can't join if you are pregnant or breastfeeding, or if you have severe chronic liver disease, especially if you have had things like hepatic encephalopathy (a brain condition due to liver disease) or cirrhosis.

Changes to your heart valves, having more than one valve replacement or repair, a history of or planned heart transplant, or a device to help your heart pump blood would also mean you can't take part. Additionally, if you've had a break from your study medicine in the past, or if you have previously been given a different medicine called luspatercept, you wouldn't be able to join this study. Participants must be 18 years or older.

As this is an extension study, you would continue to receive the study medicine, sotatercept. Researchers will regularly check your health, likely through clinic visits, physical examinations, and possibly blood tests or other scans, to monitor how you are doing over time. This helps them understand the long-term safety of the medicine and how well your body tolerates it. The exact number and frequency of visits, as well as the total duration of your participation, would be clearly explained by the study team, but the aim is longer-term follow-up than the initial study.